Clinical trials: Advanced Lung Carcinoma
Carcinoma, Non-Small-Cell Lung, Neoplasms
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
The study is primarily designed to assess the safety and tolerability of escalating oral doses of Debio 1143 and preliminary anti-tumour activity when combined with the standard dose of avelumab in participants with advanced…
- Trial name
- NCT03270176
- Testing
- Debio 1143, Avelumab
- Where
- 9 sites in Canada, Poland and 1 more
- Volunteers
- 54 people
- Sponsor
- Debiopharm International SA
Advanced Lung Cancer
CAR-T Cell Immunotherapy for Advanced Lung Cancer
The NSCLC patients who failed the standard treatments, with positive Programmed Death-Ligand 1 (PD-L1) expression, were enrolled into this trial. About 22 advanced NSCLC patients will be screened according to the criteria.
- Trial name
- NCT03330834
- Testing
- CAR-T cells to treat advanced lung cancer
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-small Cell Lung
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
The purpose of this study is to establish whether patients with malignancy harboring a discoidin domain receptor 2 mutation or an inactivating B-RAF mutation will respond to dasatinib.
- Trial name
- NCT01514864
- Testing
- Dasatinib
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 19 people
- Sponsor
- Bristol-Myers Squibb
Squamous Cell Lung Cancer
Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy
This predictive, randomized, double-blind, multi-center trial is going to evaluate the efficacy and safety of two regimens of boanmycin plus docetaxel versus docetaxel alone as a second line treatment for chemotherapy for stage…
- Trial name
- NCT01660399
- Testing
- Boanmycin, Docetaxel
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Solid Tumor
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
The primary objective of this study is to evaluate the safety of Neo-T in combination with anti-PD1 in patients with solid tumors.
- Trial name
- NCT05798533
- Testing
- Neo-T, Toripalimab, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- BGI, China
Advanced Solid Tumor, Non Small Cell Lung Cancer
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum…
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC)
- Trial name
- NCT04215978
- Testing
- BGB-A445, tislelizumab
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 204 people
- Sponsor
- BeiGene
Esophageal Cancer, Non Small Cell Lung Cancer
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer
A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal cancer and non-small cell lung…
- Trial name
- NCT03908671
- Testing
- Personalized mRNA Tumor Vaccine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Stemirna Therapeutics
Lung Cancer
Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, gemcitabine, docetaxel, paclitaxel, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00079287
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- 24 sites in Japan
- Sponsor
- Japan Multinational Trial Organization
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07624214
- Testing
- LT-010391
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Squamous-cell Non-Small-cell Lung Cancer
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
This is a phase 3 double-blinded randomized multicenter clinical trial of SCT-I10A or placebo plus docetaxel with previously treated squamous cell non-small cell lung cancer patients.
- Trial name
- NCT04171284
- Testing
- SCT-I10, Docetaxel
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Sinocelltech Ltd.
Advanced Malignant Solid Neoplasm, RAS Mutation
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed…
- Conditions
- Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
- Trial name
- NCT04678648
- Testing
- RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- RasCal Therapeutics, Inc.
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
The goal of this prospective study is to explore the safety and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with ORIENT-31 regimen (Sintilimab plus bevacizumab plus platinum-doublet chemotherapy) for…
- Trial name
- NCT06775743
- Testing
- ORIENT-31 regimen, SBRT
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Advanced Solid Tumors
Study of Intermittent OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
- Trial name
- NCT00514306
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Astellas Pharma Inc
Non Small Cell Lung Cancer
Enumeration of Circulating Tumour Cells (CTCs) in Patients With Advanced Solid Malignancy Using Complementary Metal Oxide Semiconductor (CMOS) Technology
Modern anti-cancer treatments are focused on development of molecular based therapies i.e. specific treatments targeted against underlying biological processes.
- Trial name
- NCT01596452
- Where
- Singapore
- Volunteers
- 31 people
- Sponsor
- National University Hospital, Singapore
Non-small Cell Lung Cancer
Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer
This Phase II study is to determine the efficacy of split-course thoracic radiotherapy plus concurrent chemotherapy with or without consolidation immunotherapy for patients with local advanced non-small cell lung cancer.
- Trial name
- NCT04212052
- Testing
- split-course radiotherapy, concurrent chemotherapy, consolidation immunotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer, Lung Cancer
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
The purpose of this study is to provide brigatinib for those patients with locally advanced and/or metastatic patients with ALK+ NSCLC on an expanded access basis due to their inability to meet eligibility criteria for on-going…
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
- Trial name
- NCT02784158
- Testing
- Brigatinib
- Where
- 3 sites in United States
- Sponsor
- Ariad Pharmaceuticals
Cancer, Advanced Solid Tumors
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors.
- Conditions
- Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC)
- Trial name
- NCT03893955
- Testing
- ABBV-927, ABBV-368, ABBV-181
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 150 people
- Sponsor
- AbbVie
Non Small Cell Lung Cancer
Concomitant Radio-chemotherapy in the Elderly
The purpose of this study is to evaluate the safety of non small cell lung cancer (NSCLC) treatment with cisplatin and oral vinorelbine administered weekly associated with concomitant radiotherapy in elderly patients.
- Trial name
- RACCOSA (NCT01029678)
- Testing
- Cisplatin IV, Vinorelbine, Radiotherapy
- Where
- 5 sites in France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Limoges
Neoplasm Malignant
A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification
Primary Objective: To determine objective response rate (ORR). Secondary Objectives: To assess duration of response (DR), progression free survival (PFS) and overall survival (OS). To evaluate global safety profile.
- Trial name
- NCT02435121
- Testing
- SAR125844
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Sanofi
Advanced Nonsmall Cell Lung Cancer
Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib
Studying samples of blood in the laboratory from patients receiving erlotinib may help doctors learn more about the effects of erlotinib on hormone levels.
- Trial name
- NCT00602433
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University